Actinium Pharmaceuticals Presents Preclinical Data at AACR Showing HER3 Targeted Radiotherapy Combined with the CD47 Immunotherapy Magrolimab Increases the Anti-tumor Effect ...Middle East

PR Newswire - News
Data further expand Actinium's leadership in combining targeted radiotherapy with CD47 immunotherapy in solid tumors and blood cancers Significant increase in tumor control with the HER3 ARC magrolimab combination compared to magrolimab alone in HER3-expressing NSCLC in vivo model...

Hence then, the article about actinium pharmaceuticals presents preclinical data at aacr showing her3 targeted radiotherapy combined with the cd47 immunotherapy magrolimab increases the anti tumor effect was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Actinium Pharmaceuticals Presents Preclinical Data at AACR Showing HER3 Targeted Radiotherapy Combined with the CD47 Immunotherapy Magrolimab Increases the Anti-tumor Effect )

Apple Storegoogle play

Last updated :

Also on site :